Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 1,730 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 1,730 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $28.25, for a total value of $48,872.50. Following the sale, the insider owned 78,995 shares of the company’s stock, valued at $2,231,608.75. The trade was a 2.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

CSTL opened at $31.18 on Wednesday. Castle Biosciences, Inc. has a 52-week low of $17.72 and a 52-week high of $44.28. The company has a 50 day moving average of $23.20 and a two-hundred day moving average of $26.30. The company has a market cap of $952.55 million, a P/E ratio of -47.24 and a beta of 0.98. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.34. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. The business had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. On average, analysts expect that Castle Biosciences, Inc. will post -1.29 earnings per share for the current year.

Castle Biosciences News Summary

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: BTIG raised its price target to $44 from $40 and maintained a “buy” rating. The new target implies approximately 41% upside from the referenced share price, signaling continued confidence in Castle Biosciences’ growth outlook and diagnostic-testing business. BTIG raises Castle Biosciences price target
• Neutral Sentiment: A recent report highlighted an update involving Castle Biosciences’ diagnostics business, attracting attention among healthcare investors. The available information does not provide enough detail to determine whether the update materially changes revenue or earnings expectations. Castle Biosciences diagnostics update
• Negative Sentiment: Insiders reported substantial selling activity. Derek J. Maetzold sold 28,646 shares for roughly $867,000 across July 31 and August 3, while Tobin W. Juvenal sold 19,040 shares for approximately $556,000. The transactions reduced their reported holdings, which could raise concerns about insider conviction. However, all sales were executed under pre-arranged Rule 10b5-1 trading plans, making them a weaker bearish signal than discretionary open-market selling. Castle Biosciences insider sales filing

Analysts Set New Price Targets

CSTL has been the topic of a number of recent research reports. Roth Capital started coverage on shares of Castle Biosciences in a research report on Wednesday, June 24th. They set a “buy” rating and a $40.00 target price on the stock. Robert W. Baird set a $36.00 price objective on shares of Castle Biosciences in a research report on Friday. Canaccord Genuity Group dropped their target price on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Weiss Ratings raised Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Finally, BTIG Research lifted their price objective on Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $42.00.

Institutional Trading of Castle Biosciences

Hedge funds have recently made changes to their positions in the stock. RTW Investments LP bought a new position in Castle Biosciences during the 4th quarter worth $82,283,000. Summit Partners Public Asset Management LLC boosted its holdings in shares of Castle Biosciences by 164.7% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock valued at $41,184,000 after acquiring an additional 658,725 shares during the period. Eventide Asset Management LLC acquired a new stake in shares of Castle Biosciences in the 4th quarter worth about $11,864,000. SG Americas Securities LLC lifted its position in Castle Biosciences by 1,051.8% in the 1st quarter. SG Americas Securities LLC now owns 244,886 shares of the company’s stock valued at $6,012,000 after purchasing an additional 223,624 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in Castle Biosciences during the 4th quarter valued at about $8,502,000. Institutional investors own 92.60% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.